Please login to the form below

Not currently logged in
Email:
Password:

The LionsDen Communications Award for Excellence in Payer and Policy Maker Engagement


The LionsDen Communications Award for Excellence in Payer and Policy Maker Engagement

This award recognises excellence in programmes that engage one or more key payer/stakeholder group(s) (national, regional or European) to develop and broaden debate with clinical, governmental, public and/or other stakeholders to achieve policy change that will lead to improvements in:

  • Health outcomes - delivered by challenging inequality of health outcomes, clinical care or access to medicines or services
  • Clinical practice 
  • Standards of treatment
  • Planning, coordination or delivery of services. 

Work carried out during the two-year period between January 2011 and December 2012 will be eligible.

Submissions entered previously must demonstrate how the programme has been further developed during the additional time period.

Entries are invited from:

  • Charities
  • Patient or professional associations/bodies
  • Pharmaceutical companies
  • Healthcare agencies/consultancies
  • Trade associations.

Judging criteria:

  • Analysis of the problem and evidence of customer insight
  • Quality of the strategy/tactics employed to achieve key objectives
  • Evidence of change effected through communication with national or European payers/policy makers 
  • Evidence of support from a range of interested stakeholders, e.g. healthcare professionals and patient representatives
  • Effectiveness - evidence of changed behaviours and enhanced health outcomes
  • Stakeholder/customer feedback


Sponsors

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...